velikost textu

Výsledky projektu Role farmakokinetických interakcí nových cílených léčiv v ovlivnění účinnosti cytostatik u nemalobuněčného plicního karcinomu

Výsledky

▼▲Typ výsledku ▼▲Autor celku ▼▲Název celku
(Celkem 9 zázn.)
Zhang Yu, Vagiannis Dimitrios, Budagaga Youssif, Sabet Ziba, Hanke Ivo, Rozkoš Tomáš, Hofman Jakub. Sonidegib potentiates the cancer cells’ sensitivity to cytostatic agents by functional inhibition of ABCB1 and ABCG2 in vitro and ex vivo. Biochemical Pharmacology, 2022, sv. 199, s. 115009–115009. ISSN 0006-2952. IF 6.1. [Článek v časopise]
Sonidegib (LDE-225) is a Hedgehog pathway inhibitor used for the therapy of basal cell carcinoma. Moreover, the drug is intended for the use in the treatment of non-small cell lung cancer (NSCLC). In this study, we explored its pharmacokinetic interactions and described its chemosensitizing effects. First, we found that transport functions of ABCB1 and ABCG2 were effectively inhibited by sonidegib in accumulation studies. In drug combination assays, sonidegib synergistically enhanced the cytotoxicity of daunorubicin and mitoxantrone in ABCB1- and ABCG2-overexpressing cells, respectively. Notably, similar phenomena were also observed in explant tumor cultures derived from NSCLC-suffering patients. In addition, the anticancer effects of sonidegib were not hampered by the expression of the ABC transporters associated with MDR. Last, sonidegib had no significant influence on the activity of CYP3A4 isoform in vitro. In summary, our work suggests that sonidegib can be considered a potential perpetrator of clinical DDIs on ABCB1 and ABCG2. After in vivo evaluation, its chemosensitizing properties might be projected into efficient and safe treatment regimen for the clinical management of NSCLC patients with high ABCB1/ABCG2 expression.
Sabet Ziba, Vagiannis Dimitrios, Budagaga Youssif, Zhang Yu, Novotná Eva, Hanke Ivo, Rozkoš Tomáš, Hofman Jakub. Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study. International Journal of Molecular Sciences, 2022, sv. 23, s. 14338–14338. ISSN 1422-0067. IF 6.208. [Článek v časopise]
Talazoparib (Talzenna) is a novel medication approved for the therapy of breast cancer. In addition, it has been investigated as a potential treatment for non-small cell lung cancer (NSCLC). In this study, we explored the possible inhibitory interactions of talazoparib with ABC drug efflux transporters and described its role in multi-drug resistance (MDR). In vitro accumulation studies showed that talazoparib inhibits ABCG2 and ABCC1 efflux transporters, which was confirmed by molecular docking. In in vitro drug combination experiments, talazoparib synergistically reversed mitoxantrone and daunorubicin resistance in cells with ABCG2 and ABCC1 expression, respectively. In ex vivo studies, primary cultures have been established from NSCLC biopsies excised by the pathologist after lobectomy. In the western blotting studies, differential expressions ABCG2 and ABCC1 have been detected. Subsequently, in accumulation and drug combination assays, we found an association between ABCG2/ABCC1 levels and outcomes of these experiments. In addition, talazoparib had no significant effects on the mRNA-level expressions of MDR-related ABC transporters in the MCF-7 cellular model. In summary, our study presents a comprehensive overview on the pharmacokinetic drug–drug interactions (DDI) profile of talazoparib. Moreover, we introduced talazoparib as an efficient MDR antagonist.
Dimitrios Vagiannis, Yu Zhang, Youssif Budagaga, Eva Novotna, Adam Skarka, Sarah Kammerer, Jan-Heiner Küpper, Jakub Hofman. Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter. Toxicology and Applied Pharmacology, 2021, sv. 434, s. 115823–115823. ISSN 0041-008X. IF 4.219. [Článek v časopise]
The paper focuses on alisertib, a novel Aurora A kinase inhibitor, which is currently being clinically tested in late-phase trials for the therapy of various malignancies including NSCLC. In the present work, we describe alisertib’s potential to perpetrate pharmacokinetic drug-drug interactions (DDIs) and/or to act as an antagonist of multidrug resistance (MDR). In accumulation assays, alisertib potently inhibited the ABCC1 transporter, but not ABCB1 or ABCG2. The results of molecular modeling suggested a bifunctional mechanism for interaction on ABCC1. In addition, alisertib was characterized as a low- to moderate-affinity inhibitor of recombinant CYP3A4, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 isoenzymes, but without potential clinical relevance. Drug combination studies revealed the capability of alisertib to synergistically antagonize ABCC1-mediated resistance to daunorubicin. Although alisertib exhibited substrate characteristics towards ABCB1 transporter in monolayer transport assays, comparative proliferation studies showed lack of its MDR victim behavior in cells overexpressing ABCB1 as well as ABCG2 and ABCC1. Lastly, alisertib did not affect the expression of ABCC1, ABCG2, ABCB1 transporters and CYP1A2, CYP3A4, CYP2B6 isozymes on mRNA level in various systemic and tumoral models. In conclusion, our study suggests that alisertib is a drug candidate with negligible potential for perpetrating systemic pharmacokinetic DDIs on ABCB1, ABCG2 and cytochromes P450. In addition, we introduce alisertib as an effective dual-activity chemosensitizer whose MDR-antagonistic capacities are not impaired by efflux or effect on MDR phenotype. Our in vitro findings provide important pieces of information for clinicians when introducing alisertib into the clinical area.
Dimitrios Vagiannis, Youssif Budagaga, Anselm Morell, Yu Zhang, Eva Novotná, Adam Skarka, Sarah Kammerer, Jan-Heiner Küpper, Ivo Hanke, Tomáš Rozkoš , Jakub Hofman . Pharmacokinetic interactions of tepotinib with drug efflux transporters and biotransformation enzymes: the role in combating cytostatic resistance in vitro and ex vivo. Molecular Sciences, 2021, sv. 22 , s. 11936–11936. ISSN 1422-0067. IF 5.923. [Článek v časopise]
Tepotinib is a novel tyrosine kinase inhibitor recently approved for the treatment of non-small cell lung cancer (NSCLC). In this study, we evaluated the tepotinib’s potential to perpetrate pharmacokinetic drug interactions and modulate multidrug resistance (MDR). Accumulation studies showed that tepotinib potently inhibits ABCB1 and ABCG2 efflux transporters, which was confirmed by molecular docking. In addition, tepotinib inhibited several recombinant cytochrome P450 (CYP) isoforms with varying potency. In subsequent drug combination experiments, tepotinib synergistically reversed daunorubicin and mitoxantrone resistance in cells with ABCB1 and ABCG2 overexpression, respectively. Remarkably, MDR-modulatory properties were confirmed in ex vivo explants derived from NSCLC patients. Furthermore, we demonstrated that anticancer effect of tepotinib is not influenced by the presence of ABC transporters associated with MDR, although monolayer transport assays designated it as ABCB1 substrate. Finally, tested drug was observed to have negligible effect on the expression of clinically relevant drug efflux transporters and CYP enzymes. In conclusion, our findings provide complex overview on the tepotinib’s drug interaction profile and suggest a promising novel therapeutic strategy for future clinical investigations. This GAUK project covered in vitro transporter part of the paper.
Dimitrios Vagiannis , Zhang Yu , Eva Novotna , Anselm Morell , Jakub Hofman. Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme. Biochemical Pharmacology, 2020, sv. 178, s. 1–13. ISSN 0006-2952. IF 4.960. [Článek v časopise]
The paper is focusing on entrectinib, a novel tyrosine kinase inhibitor approved in 2019 by FDA for the treatment of NSCLC. In the study, we aimed to characterize its potential to act as a modulator of pharmacokinetic cytostatic resistance and perpetrator of drug interactions. In accumulation studies, entrectinib exhibited potent inhibition of ABCB1, while only moderate interaction was recorded for ABCG2 and ABCC1 efflux transporters. Furthermore, incubation assays revealed the potential of this drug to inhibit various recombinant cytochrome P450 enzymes, which can be ranked according to inhibitory affinities as follows: CYP2C8 ≈ CYP3A4 > CYP2C9 > CYP2C19 ≈ CYP3A5 > CYP2D6 > CYP2B6 > CYP1A2. Additionally, in silico docking analysis confirmed entrectinib’s interactions with ABCB1 and CYP3A4 and resolved their possible molecular background. In subsequent drug combination experiments, we demonstrated the ability of entrectinib to synergize with daunorubicin in various ABCB1-expressing cellular models. Moreover, the comparative proliferation study results suggested that the anticancer efficacy of entrectinib is not affected by the functional presence of tested ABC transporters. In contrast to ABCB1-related data, no resistance reversal effect was recorded for the combination with docetaxel in HepG2-CYP3A4 cells. In the final experimental set, we observed no significant changes in ABCB1, ABCG2, ABCC1 or CYP3A4 gene expression in NSCLC cells exposed to entrectinib. In summary, our work indicates that entrectinib may be a perpetrator of clinically relevant pharmacokinetic drug interactions and modulator of ABCB1-mediated resistance. Our in vitro results might provide a valuable foundation for future clinical investigations.
Sabet Ziba, 205006 GAUK Sabet Ziba r.2022 [01/2022 - 12/2022], Budget billing confirmation [Jiný výsledek]
Sabet Ziba, Vagiannis Dimitrios, Budagaga Youssif, Zhang Yu, Novotná Eva, Hanke Ivo, Rozkoš Tomáš, Hofman Jakub, 13th Postdoc and PhD conference 2022 Title: TALAZOPARIB EFFECTIVELY MODULATES PHARMACOKINETIC RESISTANCE MEDIATED BY ABCG2 AND ABCC1: AN IN VITRO AND EX VIVO STUDY [Jiný výsledek]
Sabet Ziba, Budagaga Youssif, Zhang Yu, Vagiannis Dimitrios, Hanke Ivo, Rozkoš Tomáš, Hofman Jakub, 2nd International Transmembrane Transporter Society Meeting (ITTS) Title: SONIDEGIB ACTS AS A PHARMACOKINETIC RESISTANCE MODULATOR IN PATIENTDERIVED NSCLC EXPLANTS EX VIVO [Jiný výsledek]
Sabet Ziba, Vagiannis Dimitrios, Zhang Yu, Budagaga Youssif, Skarka Adam, Hofman Jakub, The presentation of 12th Postdoc and PhD conference 2022. Title: ALISERTIB ACTS AS A DUAL ACTIVITY RESISTANCE MODULATOR THROUGH THE INHIBITION OF ABCC1 TRANSPORTER [Jiný výsledek]